Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -10.65% | -1.89% | 3.78% | 12.36% | 8.61% |
| Gross Profit | 10.65% | 1.89% | -3.78% | -12.36% | -8.61% |
| SG&A Expenses | 14.17% | 31.28% | 42.23% | 28.07% | 16.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.65% | 5.79% | 11.57% | 15.76% | 10.08% |
| Operating Income | 5.65% | -5.79% | -11.57% | -15.76% | -10.08% |
| Income Before Tax | 3.40% | -12.00% | -18.39% | -25.34% | -30.62% |
| Income Tax Expenses | -- | 50.00% | -- | -- | -- |
| Earnings from Continuing Operations | 3.40% | -12.02% | -18.39% | -25.34% | -30.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.40% | -12.02% | -18.39% | -25.34% | -30.62% |
| EBIT | 5.65% | -5.79% | -11.57% | -15.76% | -10.08% |
| EBITDA | 6.16% | -5.00% | -10.46% | -14.27% | -9.44% |
| EPS Basic | 11.38% | -8.58% | -16.35% | -23.43% | -13.97% |
| Normalized Basic EPS | 13.05% | -4.35% | -16.34% | -23.43% | 5.86% |
| EPS Diluted | 11.38% | -8.58% | -16.35% | -23.43% | -13.97% |
| Normalized Diluted EPS | 13.05% | -4.35% | -16.34% | -23.43% | 5.86% |
| Average Basic Shares Outstanding | 9.00% | 3.16% | 1.75% | 1.55% | 14.60% |
| Average Diluted Shares Outstanding | 9.00% | 3.16% | 1.75% | 1.55% | 14.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |